Alnylam says Moderna used patented tech to make vaccine

Alnylam Pharmaceuticals has accused Moderna of using its nanoparticle technology to develop its COVID-19 vaccine.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

article

Silence Therapeutics settles patent dispute with Alnylam

11 December 2018 UK-based biotech company Silence Therapeutics has settled a patent dispute and entered into a licence agreement with Alnylam Pharmaceuticals.

Big Pharma

Alnylam faces declaratory relief claim over SPCs

20 October 2017 Alnylam Pharmaceuticals and The Medicines Company UK are facing a claim for declaratory relief over supplementary protection certificates requested by biotech company Silence Therapeutics.

Americas

Moderna, Pfizer face escalating COVID vaccine patent suits

14 July 2022 New lawsuit comes months after the pair were accused of infringing lipid nanoparticle technology.

More on this story

article

Silence Therapeutics settles patent dispute with Alnylam

11 December 2018 UK-based biotech company Silence Therapeutics has settled a patent dispute and entered into a licence agreement with Alnylam Pharmaceuticals.

Big Pharma

Alnylam faces declaratory relief claim over SPCs

Americas

Moderna, Pfizer face escalating COVID vaccine patent suits

14 July 2022 New lawsuit comes months after the pair were accused of infringing lipid nanoparticle technology.

More on this story

article

Silence Therapeutics settles patent dispute with Alnylam

11 December 2018 UK-based biotech company Silence Therapeutics has settled a patent dispute and entered into a licence agreement with Alnylam Pharmaceuticals.

Big Pharma

Alnylam faces declaratory relief claim over SPCs

Americas

Moderna, Pfizer face escalating COVID vaccine patent suits

14 July 2022 New lawsuit comes months after the pair were accused of infringing lipid nanoparticle technology.